ARC
GEVA

Absolute Return Capital’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Absolute Return Capital’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-12,875
Closed -$1.07M – 1530
2014
Q1 		$1.07M Buy
+12,875
New +$1.19M 0.02% 616

Other funds holding GEVA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Absolute Return Capital's GEVA Position: Q2 2014 in Review

Absolute Return Capital sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2014, closing a stake of 12,875 shares — an estimated $1.07M sold.

Absolute Return Capital first reported a position in GEVA in Q1 2014 and held it in 1 quarter. The position peaked at $1.07M in Q1 2014. 115 funds tracked by Wall St. Rank hold GEVA as of Q2 2014.

  • Absolute Return Capital reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2014 after selling out during the quarter.
  • Absolute Return Capital sold 12,875 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2014, an estimated $1.07M.
  • Absolute Return Capital first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q1 2014 and held it in 1 quarter.
  • Absolute Return Capital's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $1.07M in Q1 2014.
  • 115 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2014.

Based on Absolute Return Capital's 13F filing for Q2 2014, filed 14 Aug 2014.